Drug
Pumitamig
Pumitamig: highest development phase Phase 3, developed by BioNTech, Bristol-Myers Squibb. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioNTech, Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pumitamig NCT07173751 | Phase 3 | Breast Neoplasms |
| Pumitamig NCT07361510 | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) |
| Pumitamig NCT07361497 | Phase 3 | Non-small Cell Lung Cancer (NSCLC) |
| Pumitamig NCT06712316 | Phase 2/3 | Non-small Cell Lung Cancer |
| Pumitamig NCT07221149 | Phase 2/3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma |
| Pumitamig NCT07221357 | Phase 2/3 | Untreated, Unresectable, or Metastatic Colorectal Cancer |
| Pumitamig NCT07871214 | Phase 2 | Early-Stage Non-Small Cell Lung Cancer |
| Pumitamig NCT07297212 | Phase 2 | Recurrent Glioblastoma |
| Pumitamig NCT07293351 | Phase 1/2 | Advanced Renal Cell Carcinoma (RCC) |
| Pumitamig NCT07291076 | Phase 1/2 | Hepatocellular Carcinoma (HCC) |
Latest
No recent events.
Follow Pumitamig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.